Flash Finance

Nectar Lifesciences LimitedNECLIFECorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Mar 2026 14 quarters of data
Consolidated Standalone
₹10.54
MCap ₹205 Cr
Nectar Lifesciences Limited — Stock analysis & AI research Nectar Lifesciences Limited — Seasonality — best & worst months Nectar Lifesciences Limited — Technical setup — score, trend, support & resistance Nectar Lifesciences Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹1 Cr
Sales · Mar 2026
₹-57 Cr
Operating Profit · Mar 2026
-5700.0%
OPM % · Mar 2026
₹-68 Cr
Net Profit · Mar 2026
+47.7% YoY
₹-3.50
EPS · Mar 2026
+39.7% YoY

📝 Nectar Lifesciences Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Nectar Lifesciences Limited reported revenue of ₹1 crore for the quarter ended March 2026 (Q4 FY26).

The company reported a net loss of ₹68 crore, against a net loss of ₹130 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-3.50.

Operating profit stood at ₹-57 crore — an operating margin (OPM) of -5700.0%.

Full year and trailing twelve months

For the full year FY26, Nectar Lifesciences Limited posted revenue of ₹287 crore, a decline of 65.0% over FY25, with a net loss of ₹293 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹287 crore with a net loss of ₹293 crore.

Valuation snapshot

At the current price of ₹10.54, NECLIFE has a market capitalisation of ₹205 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 51.84%, foreign institutional investors (FIIs) 0.50%, domestic institutional investors (DIIs) 3.90%, the government 0.02%, public shareholders 43.74% of Nectar Lifesciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹205 Cr
Current Price ?
₹10.5
P/E ?
N/A
Industry P/E ?
37.20
P/B ?
0.35
P/S ?
0.71
P/FCF ?
-0.50
Enterprise Value ?
₹205 Cr
EV/EBITDA ?
-1.69
PEG ?
N/A
Earnings Yield ?
-67.4%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹287 Cr
OPM ?
-42.2%
Profit after tax (TTM) ?
₹-293 Cr
EPS (TTM) ?
₹-15.08
ROCE ?
-5.0%
ROE ?
-50.3%
ROA ?
-47.9%
Growth
Sales — latest qtr ?
₹1 Cr
PAT — latest qtr ?
₹-68 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
47.7%
Sales growth (3y) ?
-89%
Sales growth (5y) ?
-74%
Profit growth (3y) ?
3%
Profit growth (5y) ?
-4%
Financial Health
Debt ?
₹0 Cr
Debt to Equity ?
0.00
Interest Coverage ?
-2.5
Current Ratio ?
N/A
Ownership
Promoter holding ?
51.84%
Change in promoter holding ?
7.31%
Pledged percentage ?
N/A
Market
Return 3 months ?
-2.9%
Return 6 months ?
-16.8%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026 YoY % QoQ %
Sales 34438939439845244135964550281601 — —
Operating Profit 1203627424940-1450-62-0-2-57 — -2861.5%
Other Income 131801101171-130001-24 +81.5% -3732.0%
Interest 172018212524200170190306 — -80.1%
Depreciation 15151515151515016017000 — -100.0%
Profit Before Tax -183322115513-130-97-1-32-88 +32.3% -178.9%
Net Profit -952121368-130-63-17614-68 +47.7% -576.5%
EPS -0.410.240.080.050.070.030.130.250.35-5.80-2.82-7.850.64-3.50 +39.7% -646.9%
OPM % 0.4% 5.1% 9.0% 6.8% 9.3% 11.1% 11.1% -16.7% 9.8% — -22.1% -5.7% — -5700.0% — —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹820 Cr ₹287 Cr ₹287 Cr -65.0%
Operating Profit ₹84 Cr ₹-121 Cr ₹-121 Cr -245.1%
OPM % 10.18% -42.16% -42.16% -514.1%
NPM % -13.80% -101.94% -101.94% -638.7%
Other Income ₹-122 Cr ₹-23 Cr ₹-23 Cr +81.2%
Depreciation ₹31 Cr ₹17 Cr ₹17 Cr -46.0%
Interest ₹37 Cr ₹55 Cr ₹55 Cr +48.0%
EBIT ₹52 Cr ₹-138 Cr ₹-138 Cr -363.0%
PBT ₹-108 Cr ₹-217 Cr ₹-217 Cr -101.6%
Tax ₹7 Cr ₹-45 Cr ₹-45 Cr -772.0%
Net Profit ₹-113 Cr ₹-293 Cr ₹-293 Cr -158.8%
EPS ₹-5.07 ₹-13.53 ₹-13.53 -166.9%
Material Cost ₹591 Cr ₹239 Cr ₹239 Cr -59.5%
Employee Cost ₹48 Cr ₹26 Cr ₹26 Cr -47.2%
Extraordinary Items — ₹-88 Cr ₹-88 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 22222219 -13.6%
Reserves 1,0421,047934563 -39.7%
Borrowings 7546365820 -100.0%
Other Liabilities 37148650930 -94.1%
Total Liabilities 2,1892,1912,047612 -70.1%
Fixed Assets 6626436333 -99.5%
CWIP 7866570 -100.0%
Investments 11113 +1200.0%
Other Assets 1,4491,4821,357595 -56.2%
Total Assets 2,1892,1912,047612 -70.1%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 133225169-417 -346.7%
Cash from Investing Activity 52-17-421,205 +2969.0%
Cash from Financing Activity -186-205-128-699 -446.1%
Net Cash Flow -02-189 +9000.0%
Free Cash Flow 183195126-408 -423.8%
CFO/OP 244%148%-574%711% +223.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 6782760 -100.0%
Inventory Days 212215184— —
Days Payable 100127117— —
Cash Conversion Cycle 1781701430 -100.0%
Working Capital Days 77634326,741 +62088.4%
ROCE % -0%6%-5%-5% +0.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 44.53%44.91%44.91%51.84%51.84% +0.0%
FIIs 0.82%0.62%0.52%0.60%0.50% -16.7%
DIIs 0.19%0.08%0.00%0.01%3.90% +38900.0%
Government 0.02%0.02%5.84%4.03%0.02% -99.5%
Public 54.45%54.37%48.73%43.52%43.74% +0.5%
No. of Shareholders 71,97776,47078,12474,83472,334 -3.3%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 NECLIFE Nectar Lifesciences ₹10.75 209 — 287 -117 -42.2% -40.8% -21.3% -3.8% — 47.7%
❓ Frequently asked questions
What was Nectar Lifesciences Limited's revenue in Q4 FY26?
Nectar Lifesciences Limited reported revenue of ₹1 crore for the quarter ended March 2026 (Q4 FY26).
What was Nectar Lifesciences Limited's net profit in Q4 FY26?
The company reported a net loss of ₹68 crore, against a net loss of ₹130 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-3.50.
What is NECLIFE's market capitalisation and P/E ratio?
At the current price of ₹10.54, NECLIFE has a market capitalisation of ₹205 crore.
Who owns Nectar Lifesciences Limited? (shareholding pattern)
As of Sep 2026, promoters held 51.84%, foreign institutional investors (FIIs) 0.50%, domestic institutional investors (DIIs) 3.90%, the government 0.02%, public shareholders 43.74% of Nectar Lifesciences Limited.
TTM ends 2026-03-31. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI